TheTechno Optimist.

EnhertuDaiichi Sankyo—Enhertu plus pertuzumab approved in the US as first-line treatment for HER2-positive metastatic breast cancerDatrowayDaiichi Sankyo—Datroway approved in the US for first-line triple-negative breast cancer after extending survivalEnhertuDaiichi Sankyo—FDA approves Enhertu for early HER2-positive breast cancer, both before and after surgery

Datroway

by Daiichi SankyoJP

Bring the DXd payload to the many cancers that lack HER2 but carry TROP2, starting with triple-negative breast cancer, the subtype with the fewest targeted options and the worst survival.

DeployStage 4 of 5

Three US approvals; May 2026 first-line triple-negative breast cancer after a survival win.

Updated 22 May 2026Checked 11 Oct0 updates this week

Milestones

Next · EU, China and Japan reviews in triple-negative breast cancer
  1. AstraZeneca co-development dealJul 2020Complete.
  2. TROPION-Breast02 results presented (ESMO)2025Complete.
  3. FDA: first-line triple-negative breast cancer22 May 2026Complete.
  4. EU, China and Japan reviews in triple-negative breast cancerTarget 2026Current milestone.

Most important updates

Upcoming

  1. 2026EU, China and Japan reviews in triple-negative breast cancer (next)
Primer